Beth Stannard, MS, CCRP, CCRC

Beth Stannard, MS, CCRP, CCRC has a wealth of experience in clinical operations and clinical affairs. Beth began their career in 2012 as Manager of Clinical Development at InterMune. Beth then moved to Cervel Neurotech as Director of Clinical Programs in 2012. In 2015, they became Director of US Clinical Operations at BrainStorm Cell Therapeutics and Director of Clinical Operations at Scilex Pharmaceuticals. In 2016, they took on the role of Director of Clinical Affairs at Relievant Medsystems, Inc. and in 2017 they were Director of Clinical Operations at Sorrento Therapeutics, Inc. In 2018, they became Director of Clinical Operations at both ImStem Biotechnology, Inc. and Mitsubishi Tanabe Pharma America, where they were also Clinical Operations Team Leader. In 2019, they were Head of Clinical Operations at GEn1E Lifesciences Inc. and in 2021 they became Director of Clinical Operations at Biohaven Pharmaceuticals.

Beth Stannard, MS, CCRP, CCRC obtained their Bachelor of Science (BS) in Biology with minors in Chemistry, Physics, Math and Psychology from the University of Arizona between 1997 and 2000. In 2004, they obtained a Post-graduate Certificate in Clinical Trials Design & Management from the University of California, Santa Cruz. In 2008, they were certified as a Clinical Research Professional by the Society of Clinical Research Associates. In the same year, they obtained their Master of Science (MS) in Clinical Research Organization and Management from Drexel University College of Medicine. Finally, in 2003, they were certified as a Clinical Research Coordinator by the Association of Clinical Research Professionals.